Search

CN-117625443-B - Lactobacillus gasseri for improving female private health and skin aging, and composition thereof

CN117625443BCN 117625443 BCN117625443 BCN 117625443BCN-117625443-B

Abstract

The invention discloses lactobacillus gasseri for improving female private health and skin aging at the same time and a composition thereof, and belongs to the technical field of microorganisms. The invention screens and obtains a lactobacillus gasseri (Lactobacillus gasseri) CCFM1313 from the vaginal secretion of healthy females, and the lactobacillus gasseri CCFM1313 and the composition containing the lactobacillus gasseri CCFM1313, the lactobacillus paracasei CCFM1316 or the fermentation liquor thereof have the functions of repairing the oxidative damage related symptoms caused by colpitis and relieving skin aging. Therefore, the lactobacillus gasseri CCFM1313 and the composition containing the lactobacillus gasseri CCFM1313 and the lactobacillus paracasei CCFM1316 or the fermentation liquid thereof have great application prospect in improving and repairing oxidative damage caused by colpitis and products with skin health problems caused by colpitis.

Inventors

  • CUI SHUMAO
  • MAO BINGYONG
  • Lin Rumeng
  • ZHANG QIUXIANG
  • TANG XIN
  • ZHAO JIANXIN
  • CHEN WEI

Assignees

  • 江南大学

Dates

Publication Date
20260508
Application Date
20231107

Claims (8)

  1. 1. Lactobacillus gasseri (Lactobacillus gasseri) CCFM1313 was deposited at the Cantonese microorganism strain collection at 4/8 of 2023 under accession number GDMCC No:63709.
  2. 2. A microbial agent is characterized in that the microbial agent contains the lactobacillus gasseri CCFM1313 or fermentation liquor thereof as claimed in claim 1, or simultaneously contains the lactobacillus gasseri CCFM1313 or fermentation liquor thereof as claimed in claim 1 and the lactobacillus paracasei (Lacticaseibacillus paracasei) CCFM1316 or fermentation liquor thereof, wherein the lactobacillus paracasei CCFM1316 is preserved in the microorganism strain preservation center of Guangdong province at the 8 th month 4 of 2023, and the preservation number is GDMCC No:63712.
  3. 3. A product, which is characterized in that the product contains lactobacillus gasseri CCFM1313 according to claim 1 or contains the microbial agent according to claim 2, and is food, medicine or health care product.
  4. 4. A product according to claim 3, wherein the food product comprises a dietary supplement.
  5. 5. Use of the lactobacillus gasseri CCFM1313 or a fermentation broth thereof of claim 1, or the microbial agent of claim 2 for the preparation of a medicament for alleviating and/or treating bacterial vaginitis.
  6. 6. The application according to claim 5, characterized in that it comprises: (1) Up-regulating the expression of cell Nrf2 mRNA and increasing the content of cell supernatant Nrf 2; (2) Reduce colpitis mouse vaginal epithelial cell shedding; (3) Improving the vaginal pathological characterization of the mice; (4) Improving mouse vaginal oxidative stress by activating Nrf2/SOD1 pathway, and increasing the level of Nrf2 and SOD in vaginal tissue; (5) Enhancing the anti-aging capability of the skin of the mice and down regulating the expression of MAPK/AP-1/MMP-1 mRNA.
  7. 7. Use of a composition comprising lactobacillus gasseri CCFM1313 or a fermentation broth thereof and lactobacillus paracasei CCFM1316 or a fermentation broth thereof according to claim 1 in the manufacture of a medicament for alleviating and/or treating bacterial vaginitis, wherein the lactobacillus paracasei CCFM1316 was deposited at the microorganism strain deposit center in guangdong province at 8/4 of 2023 under accession number GDMCC No:63712.
  8. 8. The application according to claim 7, characterized in that it comprises: (1) Up-regulating the expression of cell Nrf2 mRNA and increasing the content of cell supernatant Nrf 2; (2) Reduce colpitis mouse vaginal epithelial cell shedding; (3) Improving the vaginal pathological characterization of the mice; (4) Improving mouse vaginal oxidative stress by activating Nrf2/SOD1 pathway, and increasing the level of Nrf2 and SOD in vaginal tissue; (5) Enhancing the anti-aging capability of the skin of the mice and down regulating the expression of MAPK/AP-1/MMP-1 mRNA.

Description

Lactobacillus gasseri for improving female private health and skin aging, and composition thereof Technical Field The invention relates to lactobacillus gasseri and a composition thereof for simultaneously improving female private health and skin aging, belonging to the technical field of microorganisms. Background The colpitis is a common colpitis infectious disease of women of childbearing age, has the characteristics of high recurrence rate and atypical clinical symptoms, and is easy to leak in clinic. Pathogenic bacteria invading into the vaginal environment adhere to epithelial cells of the genital tract to release toxins to cause cell mitochondrial injury, generate a large amount of Reactive Oxygen Species (ROS), promote imbalance of the redox reaction system of the organism and cause oxidative damage. Transcription factor nuclear factor-erythrocyte-related factor 2 (Nrf 2) is an important antioxidant transcription factor, and in normal conditions, nrf2 is kept at a low level in cytoplasm, and researches prove that probiotics can improve the expression quantity of Nrf2 genes and proteins and increase the anti-inflammatory and antioxidant capacities of cells through activating Nrf2 signal channels. Simultaneously, nrf2 can synergistically enhance the effect of superoxide dismutase (SOD) to induce oxidative stress reaction. MAPK is an intracellular threonine protein kinase that can be activated by ROS extracellular, activating transcription factor AP-1 to further regulate transcription of MMPs, especially interstitial collagenase (MMP-1), stromelysin-1 (MMP-3) and gelatinase (MMP-9) of the MMP family, leading to degradation of collagen and elastin. Currently, the drugs selected for the treatment of vaginitis mainly include nitroimidazoles (metronidazole, tinidazole) and lincomycin (clindamycin). However, antibiotics cannot repair the vaginal environment damaged by oxidative stress, and the risk of recurrence of vaginitis is high and not low. Studies show that the recurrence rate can be obviously reduced by using lactobacillus viable bacteria capsules in the treatment of recurrent vaginitis. In addition, by comparing the efficacy of 3 single strains with that of a compound probiotic formula containing the corresponding single strains, the results show that the single or compound probiotics can both effectively promote the immune function of mice, and the treatment effect of the compound probiotics is more remarkable. Therefore, the combined use of multiple strains can generate a synergistic effect, enhance the viability of the strains and continuously, stably and comprehensively regulate the organism. At present, local probiotic products for the treatment of vaginitis are very limited on the market. Kang Bai is equal to 1989, and a Lactobacillus delbrueckii DM8909 strain is separated and screened from vaginal secretion of healthy women, and the initial test (study on inhibiting mouse vaginal infection by Lactobacillus DM8909 strain, journal of China microecology, 2003) and clinical data (study on phase II clinical test of bacterial vaginosis treatment by Lactobacillus delbrueckii DM8909 strain, journal of China microecology, 2001) show that the strain has good probiotic characteristics and effects of treating bacterial vaginosis. In addition, some of the patents relate to probiotic compositions for vaginitis, mainly modulating the factors of vaginal inflammation (CN 110339216A, CN 111647525A). However, the effect of probiotic compositions on antioxidant capacity was not reported and no corresponding study was made of oxidative damage to vaginitis. Thus, there is no mechanism to elucidate lactobacillus gasseri and compositions thereof that are clearly useful for alleviating bacterial vaginitis and vaginal oxidative damage caused by vaginitis and skin health. Disclosure of Invention The invention provides a lactobacillus grignard which can relieve vaginitis, improve oxidative damage caused by vaginitis and skin health problems caused by vaginitis, and the lactobacillus grignard CCFM1313 has good in vitro capacity of activating Nrf2 expression and improving the concentration of Nrf2 in a culture supernatant of vaginal epithelial cells, and has the capacity of potentially relieving the oxidative stress of the vaginitis. SPF-grade BALB/c mice, females, 7 week old, and body weights of 18-20g were selected. Mice were injected with estradiol valerate three consecutive days after the adaptation period and were induction-treated for estrus. Infection with gardnerella vaginalis was continued for 5 days, once daily. The specific operation method of the infection is to prepare 10 10 CFU/mL gardnerella vaginalis suspension with the dosage of 20 mu L/mouse. 20 mu L of the bacterial suspension is sucked by a gun head and slowly injected into the vagina of the mouse, the mouse is inverted and stays for 1-2 minutes, and the mouse is placed in a cage. The mice with vaginitis models are divided into a model group and an int